U.S. Biotech Stock News

Why DLocal Stock Is Back on Investors’ Radar DLocal (NasdaqGS:DLO) has drawn fresh attention after shifting to a majority independent board and appointing a new CFO, with robust EBITDA performance helping spark several analyst upgrades and renewed interest in the shares. See our latest analysis for DLocal. Those board and CFO changes, together with solid EBITDA execution, come after a mixed stretch where the 1 year total shareholder return of 28.41% contrasts with a 7.82% total shareholder...

In recent days, Fortune Brands Innovations drew attention after President Donald Trump directed the Federal Housing Finance Agency to buy US$200.00 billion in mortgage bonds to counter the Federal Reserve’s mortgage‑backed securities runoff and support U.S. housing affordability. This large policy move ties the company’s prospects even more closely to government efforts to stabilize housing finance, a key underpinning for renovation and new‑build activity. We’ll now examine how this large...

Canaan Inc. recently announced a 3.0 MW proof-of-concept with Bitforest Investment in Manitoba, where its Avalon liquid-cooled computing servers will recycle waste heat to support greenhouse operations while targeting high uptime and low power costs. This project highlights how bitcoin mining infrastructure can be repurposed as an energy-efficient heat source for agriculture, potentially broadening Canaan’s role beyond traditional mining hardware. We’ll now examine how this heat-reuse...

EXL, a global data and AI company, was recently recognized as a Leader in five quadrants of the ISG Provider Lens™ Insurance Services 2025 report, covering specialist capabilities, Life & Retirement, Property & Casualty, GenAI, Agentic AI, and Global Capability Centers. This leadership across multiple insurance and AI-led categories highlights EXL’s broad role in modernizing complex insurance workflows and strengthening its position as an end-to-end partner for insurers. Next, we’ll examine...

In recent days, multiple major brokerage firms have reiterated positive ratings on Charles Schwab, reflecting strong confidence in its position across retail brokerage, banking, and asset management. This broad analyst optimism, highlighted by consistent “Outperform” and “Buy” recommendations, underscores how Schwab’s diversified business model is shaping market expectations for the firm. Next, we’ll examine how this wave of upbeat analyst sentiment may influence Charles Schwab’s existing...

Recently, Medpace Holdings was highlighted for its role in outsourced clinical trials and medical research, with analysts pointing to strong organic growth and an improving biotech funding backdrop that supports its expansion plans across multiple therapeutic areas. The company’s focus on digital health tools, AI-powered analytics, and selective acquisitions is seen as a way to capture more clinical research demand while addressing workforce and cost pressures in the contract research...

If you are wondering whether ADMA Biologics at US$18.28 is pricing in too much optimism or still leaves room on the table, the starting point is understanding how its current price lines up against its underlying value. The stock has had a mixed run, with a 2.9% decline over the last 7 days and a 7.3% decline over the last 30 days, while still showing a 2.2% gain year to date and a 9.4% return over the last year. Over a longer window, the share price change over three years translates into a...

If you are wondering whether Chipotle Mexican Grill's current share price makes sense, this article will help you connect the recent moves in the stock to what the business may be worth. The shares most recently closed at US$40.59, with returns of 4.4% over 7 days, 12.9% over 30 days, 8.3% year to date, 34.2% over 3 years and 37.1% over 5 years, alongside a 29.2% decline over the last 12 months. Recent headlines around Chipotle have focused on its brand strength, store expansion and ongoing...

If you are wondering whether Energy Transfer's current price gives you good value for the risk you are taking, you are not alone. The stock recently closed at US$17.50, with returns of 5.9% over 7 days, 6.1% over 30 days, 5.5% year to date, and a 6.0% decline over the last year, while the 3 year and 5 year returns sit at 79.6% and a very large gain respectively. Recent coverage around Energy Transfer has focused on its role in the US energy infrastructure space and ongoing interest from...

Why OPKO Health is on investors’ radar today OPKO Health (OPK) has drawn attention after recent trading left the share price at $1.30, with the stock showing mixed returns over the past week, month, past 3 months, and year. See our latest analysis for OPKO Health. At the current US$1.30 share price, OPKO Health’s recent 1 day and 3 month share price declines, alongside a 1 year total shareholder return loss of 11.56%, suggest that momentum has been fading, even though there has been a small...

If you are wondering whether AST SpaceMobile's current share price fairly reflects its potential, you are not alone. Many investors are trying to work out what a sensible value looks like here. The stock has been highly active, with returns of 11.1% over the past 7 days, 40.4% over 30 days, 14.1% year to date and 342.1% over 1 year. The 3 year return is very large at about 18x, and the 5 year return stands at 493.6%. Recent headlines have focused on AST SpaceMobile's progress in building a...

DocuSign (DOCU) recently rolled out AI powered upgrades to its eSignature platform, simplifying contract summaries and automating document preparation. The stock has since seen mixed reactions as investors reassess its position in AI driven software. See our latest analysis for DocuSign. The AI launch comes after a choppy period for the stock, with a 1 day share price return of 4.09% decline and a 7 day share price return of 11.07% decline. The 1 year total shareholder return of 32.26%...

Why a shareholder investigation is drawing fresh attention to Molina Healthcare (MOH) Grabar Law Office has launched a shareholder investigation into Molina Healthcare (MOH), focusing on alleged failures to disclose medical cost trends, premium misalignment, service utilization assumptions, and potential cuts to 2025 financial guidance. See our latest analysis for Molina Healthcare. The investigation headlines arrive after a sharp short term rebound, with a 1 month share price return of...

C3.ai has recently been under pressure as revenue declines, operating losses widen, leadership changes add uncertainty, and analysts expect further year-over-year drops in earnings and sales. At the same time, persistent insider share sales and mixed analyst opinions highlight growing concern over whether C3.ai can convert AI interest into sustainable enterprise demand. We’ll now examine how these mounting operational challenges and cautious sentiment could reshape C3.ai’s investment...

Occidental Petroleum (OXY) is back in focus after its carbon capture subsidiary, 1PointFive, agreed to sell 9,000 metric tons of Direct Air Capture carbon removal credits to Bain & Company over a three-year period. See our latest analysis for Occidental Petroleum. That 1PointFive deal lands at a time when interest in Occidental’s carbon management story is building again, with a 7 day share price return of 8.12% and a 30 day share price return of 10.28%, even though the 1 year total...

Eos Energy Enterprises (EOSE) is back in focus after unveiling its new Eos Indensity architecture and preparing for its “Eos in Focus” webcast, events that are concentrating attention on the stock and the underlying business. See our latest analysis for Eos Energy Enterprises. Those product and event updates come after a period of sharp moves, with a 7 day share price return of 23.75% and a year to date share price return of 33.38%. This is set against a 1 year total shareholder return of...

NCR Atleos Corporation recently announced a collaboration with Epirus Bank to modernize the bank’s ATM network across Greece using its ATM as a Service model, including lifecycle services such as location selection, installation, maintenance, and operational support for new co-branded Epirus Bank–Cashzone ATMs. This agreement highlights how NCR Atleos can deepen its presence in European markets by running outsourced, branded ATM networks that help banks cut operating complexity while...

Bank of America (BAC) FY 2025 earnings snapshot Bank of America (BAC) has wrapped up FY 2025 with fourth quarter revenue of US$27.1b and basic EPS of US$0.99, supported by trailing twelve month revenue of US$107.4b and EPS of US$3.86. The bank has seen revenue move from US$96.1b and EPS of US$3.25 on a trailing basis at the end of 2024 to US$107.4b and US$3.86 respectively, while FY 2025 net income excluding extra items came in at US$29.1b. Together with a trailing net profit margin of 27%...

Borr Drilling Limited recently announced new contract commitments for its Ran and Odin jack-up rigs, extending work in Mexico through March 2026 and securing a multi-well campaign in the United States starting in mid-2026. These contracts add visibility to Borr Drilling's future workload and highlight continued customer demand for its premium shallow-water fleet in the Americas. Next, we’ll examine how this added contract visibility for the Ran and Odin rigs influences Borr Drilling’s...

Why FactSet’s new shelf registration matters for shareholders FactSet Research Systems (FDS) has filed a shelf registration for up to US$1.245b in common stock, tied to an ESOP related offering of 4,232,362 shares. This filing is drawing fresh attention to potential dilution and capital allocation. See our latest analysis for FactSet Research Systems. The shelf registration lands after a mixed stretch for investors, with a 90 day share price return of 6.21% and a 1 year total shareholder...

TG Therapeutics (TGTX) drew attention after using its J.P. Morgan Healthcare Conference slot to share preliminary 2025 revenue figures for BRIUMVI and to outline 2026 revenue targets, giving investors fresh information on current business momentum. See our latest analysis for TG Therapeutics. The revenue guidance shared at the J.P. Morgan Healthcare Conference comes after a 1-day share price return of 5.99% to US$29.54, compared with a 30-day share price decline of 5.95%. The three year total...

If you are wondering whether Robinhood Markets at US$119.67 is still offering value after its big run, this article will walk through what the current price may be implying. The stock has returned 3.7% over the last 7 days, 0.2% over the last 30 days, 3.9% year to date, 159.7% over the last year, and a very large 3 year return. Recent discussion around Robinhood has focused on its role as a major retail trading platform and how that positioning could affect investor expectations, especially...

If you have ever wondered whether Ferrari shares still justify their premium price tag, you are not alone, as many investors are asking what a fair value looks like today. The stock last closed at US$353.39, with a 3.7% decline over 7 days, a 4.1% decline over 30 days, a 5.0% decline year to date, but a 50.6% gain over 3 years and 70.9% over 5 years. These mixed returns over different time frames have kept Ferrari on many watchlists, as investors reassess what they are willing to pay for the...

In January 2026, Veracyte released preliminary, unaudited results and earnings guidance, projecting fourth-quarter 2025 revenue of US$138 million to US$140 million and full-year 2025 revenue of US$515 million to US$517 million, alongside an outlook for 2026 revenue of US$570 million to US$582 million. The company also highlighted expected adjusted EBITDA margins around 25% and plans to launch Prosigna and its TrueMRD platform in the US, underscoring its focus on expanding its cancer...